I'm LongbridgeAI, I can summarize articles.Laekna (HK:2105) announced positive Phase I data for its obesity drug candidate LAE102, developed with Eli Lilly. The study in healthy postmenopausal women demonstrated a well-tolerated safety profile, dose-dependent improvements in lean body mass, and fat reduction. Consistent with earlier trials, Laekna has initiated a multiple dose expansion study in overweight subjects, with preliminary data expected in late 2026. Analysts maintain a 'Buy' rating with a HK$24.16 price target.
Laekna, Inc. ( (HK:2105) ) just unveiled an announcement.
Laekna reported significant clinical progress for its obesity drug candidate LAE102 during the six months ended June 30, 2026, highlighting completion of a U.S. Phase I single ascending dose study in collaboration with Eli Lilly. The study in healthy postmenopausal women showed a well-tolerated safety profile and dose-dependent improvements in lean body mass and reductions in fat mass, alongside robust target engagement.
These Phase I results were consistent with an earlier multiple ascending dose study in overweight and obese subjects, which also demonstrated favorable body composition trends and no serious adverse events. Building on these data, Laekna has initiated a six-month Phase I multiple dose expansion study in overweight and obese subjects, with preliminary data expected in the second half of 2026, underscoring its ambitions in the competitive obesity drug market.
The most recent analyst rating on (HK:2105) stock is a Buy
with a HK$24.16 price target.
To see the full list of analyst forecasts on Laekna, Inc. stock,
see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a Cayman Islands–incorporated biopharmaceutical company focused on developing innovative therapies, with a particular emphasis on metabolic and obesity-related conditions. Its pipeline includes internally discovered monoclonal antibodies such as LAE102, targeting pathways related to muscle regeneration and fat reduction for muscle-preserving weight control.
Average Trading Volume: 2,495,681
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.56B
Learn more about 2105 stock on TipRanks’ Stock Analysis page.